2 Information about elosulfase alfa

Marketing authorisation indication

2.1

Elosulfase alfa (Vimizim, Biomarin) is licensed to treat 'mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages'.

Dosage in the marketing authorisation

Price

2.3

The price for elosulfase alfa is £750 per 5‑mg vial (excluding VAT; BNF online accessed October 2021). The company has a commercial arrangement. This makes elosulfase alfa available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)